Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2007 Oct;9(5):505-14.

Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.

Author information

1
University of Pittsburgh School of Medicine, Melanoma and Skin Cancer Program, 5150 Centre Avenue, 5th Floor Pittsburgh, PA 15232, USA. tarhiniaa@upmc.edu

Abstract

Pfizer Inc is developing tremelimumab, a fully human monoclonal IgG2 antibody against cytotoxic T-lymphocyte-associated antigen, for the potential intravenous treatment of cancer. Phase III clinical trials to confirm the role of tremelimumab in the treatment of metastatic melanoma are ongoing, as are phase II trials in patients with NSCLC and colorectal cancer.

PMID:
17932815
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center